logo-loader
AIM ImmunoTech Inc.

Hemispherx Biopharma appoints Ellen Lintal as chief accountant

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Tom Equels tells Proactive Investors the biotech company has promoted Ellen Lintal as its new chief accounting officer, from vice-president of finance and control.

Equels says Lintal has experience with M&A, which Equels says, will advance the company's business plan.

Quick facts: AIM ImmunoTech Inc.

Price: $2.10

Market: NYSE
Market Cap: $5.13 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

hVIVO PLC's 2020 pipeline 'looking strong' as it expands service offerings

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

9 hours, 46 minutes ago

2 min read

;